Afimkibart + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderately to Severely Active Ulcerative Colitis
Conditions
Moderately to Severely Active Ulcerative Colitis
Trial Timeline
Dec 11, 2024 → Dec 30, 2029
NCT ID
NCT06588855About Afimkibart + Placebo
Afimkibart + Placebo is a phase 3 stage product being developed by Roche for Moderately to Severely Active Ulcerative Colitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06588855. Target conditions include Moderately to Severely Active Ulcerative Colitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07137598 | Phase 2 | Recruiting |
| NCT06863961 | Phase 2 | Recruiting |
| NCT06588855 | Phase 3 | Recruiting |
Competing Products
7 competing products in Moderately to Severely Active Ulcerative Colitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CT-P13 SC Auto-Injector + Placebo Auto-Injector | Celltrion | Phase 3 | 77 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| Afimkibart | Roche | Phase 3 | 77 |
| Afimkibart | Roche | Phase 3 | 77 |
| Obefazimod | Abivax | Phase 2 | 49 |